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Summary
Leukoencephalopathy with vanishing white matter
(VWM) is an autosomal recessive disorder with normal
early development and, usually, childhood-onset neu-
rological deterioration. At present, diagnosis of VWM
is based on clinical examination and the results of re-
peat magnetic resonance imaging and magnetic reso-
nance spectroscopy, which show that, with time, in-
creasing amounts of the cerebral white matter vanish
and are replaced by cerebrospinal fluid. We have per-
formed a genome linkage screening of a panel of 19
families of different ethnic origins. Significant linkage
to chromosome 3q27 was observed in a 7-cM interval
between markers D3S3730 and D3S3592, with a max-
imum multipoint LOD score of 5.1 calculated from the
entire data set. The results of genealogical studies have
suggested that seven parents in four Dutch families with
VWM may have inherited an allele for the disease from
a common ancestor who lived at least eight generations
ago. Analysis of these families provided further evi-
dence for the localization of the gene for VWM to
3q27. The patients shared a haplotype spanning 5 cM
between markers D3S1618 and D3S3592. In one fam-
ily of a different ethnic background, the patient had,
in the same region, homozygosity for 13 consecutive
markers spanning at least 12 cM, suggesting consan-
guinity between the parents. A healthy sibling of this
patient had the same homozygous haplotype, which
suggests that the healthy sibling is presymptomatic for
the disease.
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Introduction
A new disease entity among leukoencephalopathies of
unknown origin has recently been defined on the basis
of a characteristic clinical course and the findings of
magnetic resonance imaging (MRI) and magnetic reso-
nance spectroscopy (MRS) (Hanefeld et al. 1993; Schiff-
mann et al. 1994; Tedeschi et al. 1995; van der Knaap
et al. 1997, 1998). The condition is variously referred
to as “childhood ataxia with central hypomyelination”
(Schiffmann et al. 1994) and “leukoencephalopathy
with vanishing white matter” (VWM; MIM 603896)
(van der Knaap et al. 1997). The initial development of
the patient is normal or close to normal. The onset of
neurological deterioration usually occurs in late infancy
or early childhood (Hanefeld et al. 1993; Schiffmann et
al. 1994; van der Knaap et al. 1997), but juvenile- and
even adult-onset cases have been described (van der
Knaap et al. 1998). The neurological signs of VWM
include progressive cerebellar ataxia, spasticity, variably
present optic atrophy, and relatively preserved mental
abilities. The course of the disease is chronic progressive,
and, in most patients, additional episodes of rapid de-
terioration occur after febrile infection or minor trauma
to the head. MRI findings have shown a diffuse abnor-
mality of the cerebral white matter from the presymp-
tomatic stage onward (van der Knaap et al. 1997, 1998).
The results of both MRI and MRS have provided evi-
dence that, in time, increasing amounts of the abnormal
white matter vanish and are replaced by cerebrospinal
fluid. Autopsy findings have confirmed the presence of
white-matter rarefaction and cystic degeneration (van
der Knaap et al. 1997, 1998).
Family data have indicated that VWM has an au-
tosomal recessive inheritance with age-dependent pen-
etrance. We performed a genomewide analysis to de-
termine the genetic linkage between VWM and
polymorphic microsatellite markers. The data for
analysis were gathered from 19 families from diverse
populations. Two patients were the result of consan-
guineous matings, and there were five multiplex fam-
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Figure 1 Pedigrees of informative families with VWM. Families
1 and 4 are from The Netherlands, families 3, 5, and 6 are from the
United States, and family 2 is of Mediterranean origin. The parents
of family 2 are first cousins once removed. The patients from families
2, 4, and 5 were included in the genomewide linkage analysis. All
individuals were included in the second round of analysis of the re-
sulting candidate regions. For these six families, the estimated maxi-
mum two-point LOD score was 4.7.
ilies that each included two patients. The search strat-
egy involved genomewide screening of a limited
number of patients. Resulting candidate regions for
the gene were analyzed, with the use of closely spaced
markers, in all the families. The gene for VWM was
assigned to chromosome 3q27, and there was no ev-
idence for locus heterogeneity.
Patients and Methods
Patients
The diagnosis of VWM was confirmed in all patients
by expert examination of clinical data and MRI scans
(by M.S.v.d.K.). The criteria for the diagnosis of VWM
have been described in detail elsewhere (van der Knaap
et al. 1997, 1998). After consent was obtained both from
the patients’ parents (and, if possible, the patients) and
from the medical ethics committee of Free University
Hospital, Amsterdam, samples of DNA were collected
from a panel of 19 informative families, including 5
families from The Netherlands, 7 white families from
the United States, 2 families from Canada, and 1 family
each from the United Kingdom, Italy, Portugal, Turkey,
and Germany. The panel contained five multiplex fam-
ilies. In two other families, in which the parents were
consanguineous, the inbreeding coefficients for the pa-
tients were .25 and .03. The remaining families all in-
cluded a single patient with one or two healthy siblings.
Altogether, the study comprised 23 patients and 18
healthy siblings was gathered. The parents of one mul-
tiplex family were examined by use of MRI and were
found to be unaffected. None of the parents had neu-
rological signs of VWM.
Genotyping
A genomewide scan incorporating 358 markers from
the Marshfield screening set, version 6.0 (Center for
Medical Genetics, 1998), was performed on five patients
from three families (fig. 1). These patients included one
affected child of a consanguineous mating (vwm18) and
two pairs of affected brothers (vwm32-vwm33 and
vwm36-vwm37). The average spacing of the marker set
was 10.9 cM.We scored a marker as being positivewhen
at least two of the three families met our first-level
screening criterion. The criterion for the patient from
consanguineous parents was homozygosity, and the cri-
terion for the affected sib-pairs was sharing. When two
adjacent markers were positive, the region was also an-
alyzed in the three remaining multiplex families (fig. 1).
Regions that were indicative of linkage in at least four
of the six families were finally characterized, by use of
closely spaced markers from the Centre d’E´tude du Po-
lymorphisme Humain (CEPH) linkage map (Dib et al.
1996), in all 19 families.
The marker alleles in individual samples of DNAwere
analyzed, by use of PCR of the polymorphic microsat-
ellite region, with oligonucleotide primers that were la-
beled with the fluorophores 6-FAM, HEX, or TET. PCR
was performed in a volume of 10 ml with 50 ng genomic
DNA; 10 pmol of each primer; 200 mM each of dATP,
dGTP, dCTP, and dTTP; 0.4 U Taq DNA polymerase;
20 mM Tris-HCl pH 8.5; 50 mM KCl; 1.5 mM MgCl2;
0.005% Tween-20; and 0.005% Nonidet P40. The in-
itial denaturation step was done at 95oC for 3 min, then
30 cycles at 95oC for 30 s, 55oC for 30 s, and 72oC for
30 s. The final reaction step, which was performed in a
GeneAmp 9600 thermocycler (Perkin-Elmer), was done
at 72oC for 30 min. The PCR-product lengths were de-
termined by use of automatic instrumentation (Perkin-
Elmer ABI Prism 310 Genetic Analyzer). DNA obtained
from CEPH individual 134702 was analyzed and was
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Figure 2 Results of the first stage of the genomewide scan for
linkage of polymorphic microsatellite markers to the phenotype of
VWM. The blocks represent the results for the ordered markers of the
genomewide set on the numbered chromosomes. The left segment of
a block indicates the result of the marker with genomic DNA from
patient vwm18, who has consanguineous parents. An unblackened,
unshaded segment indicates homozygosity of the marker, and a gray-
shaded segment indicates heterozygosity. The middle and right seg-
ments indicate the results in affected sib-pairs vwm32-vwm33 and
vwm36-vwm37, respectively. An unblackened, unshaded segment in
these areas means that the siblings have the same allelotypes, a gray-
shaded segment means that they differ in one allele, and a blackened
segment indicates that they have no allele in common. Lines indicate
the relative positions of the telomeres. Open spaces represent markers
that failed to produce results. Circles indicate regions with a possible
location of a gene for VWM, on the basis of results from at least two
families, for two or more adjacent markers. The unblackened circle
denotes the region of chromosome 3 that showed significant linkage
after analysis of all families. The corresponding markers, D3S2427
and D3S2398, are 20 cM apart from each other.
considered the standard for DNA-fragment lengths (Dib
et al. 1996).
Statistical Analysis of Linkage
Multipoint LOD scores were calculated, for 14
markers on chromosome 3, with the MAPMAKER/
HOMOZ computer program (Kruglyak et al. 1995);
a recessive mode of inheritance with no phenocopies
and with complete penetrance in homozygous indi-
viduals was assumed. Allele frequencies for the mark-
ers were calculated from the available family material.
In the analysis, the order of and distances between
markers were as follows: D3S3715–2 cM–[D3S3511,
D3S3730]–1 cM–[D3S3699, D3S3662, D3S3603]–
2 cM–D3S1618–2 cM– [D3S3583, D3S3578,
D3S3609]–3 cM–[D3S3592, D3S1617]–3 cM–
D3S3570–3 cM–D3S3686. Since the exact age-at-on-
set distribution of VWM is not known and since it
may vary both within and between families, the extent
to which the data on the patients’ clinically unaffected
siblings should contribute to the calculation of LOD
scores was uncertain. Therefore, an additional mul-
tipoint LOD-score analysis was done; this additional
analysis, in which a very low penetrance was assumed
for homozygous affected individuals (.001), can be
regarded as an “affecteds-only” analysis.
Results
A genomewide search for the VWM gene was per-
formed in two affected sib pairs and in a patient from
a consanguineous marriage (fig. 1). The results of the
genomewide scan are displayed in figure 2. Thirteen sets
of markers fulfilled our criteria for sharing and/or ho-
mozygosity at the first stage of the screen (fig. 2). These
genomic regions were investigated in the three additional
multiplex families. Regions for which the results re-
mained indicative of linkage in at least four of the fam-
ilies were analyzed with closely spaced markers. In these
families, evidence for the location of a gene for VWM
at chromosome 3q27 was obtained with the use of
marker D3S3578 (two-point LOD score 3.6; recombi-
nation frequency, 0%). We further analyzed the remain-
ing families, and the most informative haplotypes are
displayed in figure 3. The recombinants in the multiplex
families were indicative of a region between markers
D3S3730 and D3S3592 as being the most likely location
of the gene for VWM. Results for all but one family
were consistent with localization of the gene to chro-
mosome 3q27. In the family whose results were incon-
sistent with this finding, a healthy adult sibling dis-
played, for the region, a genotype that was identical to
that in the index patient (fig. 3, vwm44 and vwm46).
Both the patient and the healthy sibling were homozy-
gous for 13 consecutive markers in the critical region of
chromosome 3.
Multipoint analysis, done with the use of information
obtained only from affected individuals, provided a
maximum multipoint LOD score of 5.1 for a broad re-
gion between markers D3S3730 and D3S3592 (fig 4).
When analysis was done with an assumption of complete
penetrance, the maximum multipoint LOD score
reached 3.8 in this region (fig. 4).
Narrowing the Region for VWM, on the Basis of
Haplotype Sharing in Dutch Families
Genealogical evaluation of seven generations indi-
cated that the ancestors of seven parental lineages of
four Dutch families with six VWM patients lived in the
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Figure 3 Informative haplotypes from chromosome-region 3q27 in families with VWM. The haplotypes are based on the genotypes of
the parents. Alleles for markers of the listed loci are given as PCR-product lengths. Gray-shaded bars indicate the positions of recombination
events.
same rural area, around the city of Z., in the eastern
part of The Netherlands. This geographic clustering
strongly suggested that (1) a mutant allele was intro-
duced, by a common ancestor of these families, into the
area of Z. and (2) the patients in these families are ho-
mozygous for the same allele and for the surrounding
genomic region. Patients vwm3, vwm4, vwm32, vwm33,
and vwm90, who are from three of these families, were
all indeed homozygous for the same haplotype of five
markers between loci D3S1618 and D3S3592, with the
exception that patients vwm3 and vwm4 inherited allele
169 at D3S3609 (fig. 5). The 6th patient, vwm98, had
a single copy of the haplotype, except in the case of the
allele at D3S1618. This haplotype was inherited from
the patient’s mother, whose ancestors lived near Z. One
copy of the common haplotype is also shared by the
affected sib-pair vwm36-vwm37 and by patient vwm80
from the United States (fig. 5). The results of this study
indicated that the gene for VWM is located in the region
between markers D3S1618 and D3S1617. The afore-
mentioned results, when combined, show that the lo-
cation for the gene for VWM can be narrowed to a 5-
cM region between markers D3S1618 and D3S3592.
Discussion
We have assigned the gene for VWM to chromosome
3q27, by use of a strategy that included a genomewide
search in a limited number of patients. The patients in-
cluded one individual whose parents were first cousins
once removed. Homozygous genomic regions that are
identical, on the basis of descent from a single ancestor
of this patient, are expected to span a genetic distance
of ∼25 cM (TeMeerman et al. 1995). The DNAmaterial
further consisted of samples from two affected sib-pairs.
Genomic regions shared by siblings are generally 125
cM. The polymorphic marker set that we used has an
average spacing of 10.9 cM. Our decision to apply a
relatively loose criterion (results consistent for linkage,
in two of three families, for two adjacent markers,) at
the first level of the screen proved to be of great value.
If we had applied the more strict criterion that the find-
ings in all three families should be consistent with link-
age, the currently implicated region would not have been
identified. The two markers that directed us to the cur-
rent location for the gene for VWM span 20 cM, and
only the findings in the patient who had consanguineous
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Figure 4 Multipoint LOD scores for linkage of VWM to chromosome 3q27. LOD scores were calculated, by use of the MAPMAKER/
HOMOZ computer program, from the data for 19 families with VWM. The LOD scores were calculated (see the Statistical Analysis of Linkage
section of the text), with an assumption of either complete penetrance or a penetrance of .001 for homozygous affected individuals. Capital
letters indicate the position of markers. A = D3S3715, B = D3S3511-D3S3730, C = D3S3699-D3S3662-D3S3603, D = D3S1618, E = D3S3583-
D3S3578-D3S3609, F = D3S3592-D3S1617, G = D3S3570, and H = D3S3686.
parents indicated linkage with both markers (fig. 2). Re-
sults for each of the two affected sib-pairs suggested
linkage with only one of the two markers. Conclusive
evidence for the assignment of the gene for VWM to
chromosome 3, between loci D3S1618 and D3S3592,
came from the analysis of the complete panel of 19
families.
Only one family had results that were in apparent
conflict with this localization. In this family, which did
not have known consanguinity, a patient and a healthy
adult sibling are identical and homozygous for the crit-
ical region. Given that the frequency of the disease allele
must be very low, we suggest that (1) as a result of distant
consanguinity between the parents, the patient in this
family is homozygous, by descent, for a mutation in the
gene for VWMon chromosome 3q27 and (2) the healthy
sibling is presymptomatic. As described elsewhere, sim-
ilar phenotypic variation has been seen in an affected
individual and in the individual’s presymptomatic adult
sibling who had MRI findings typical for VWM (van
der Knaap et al. 1998). We could not evaluate this ap-
parently healthy sibling by use ofMRI, because of ethical
considerations. This single unaffected individual with
the at-risk genotype provides the explanation for the
observed differences between the regular multipoint
LOD-score analysis (maximum, 3.8) and the affecteds-
only analysis (maximum, 5.1). Our results confirm the
autosomal recessive mode of inheritance of the disease
and suggest that a single locus is involved in the etiology
of VWM.
Genealogical studies indicated that a single ancestor
introduced the gene for the disease in four Dutch ped-
igrees. A common haplotype for the critical region of
chromosome 3q27 was identified in the corresponding
patients, thereby confirming the assignment of the gene
for VWM. The observed haplotype sharing is particu-
larly striking, since the constituting alleles of markers
D3S3583, D3S3578, D3S3609, and D3S3592 have a
combined frequency of only 1.3/10 000. In patients
vwm3 and vwm4, allele 169 at marker D3S3609 may
have been mutated from allele 171 somewhere in the
ancestral lineage. D3S3609 is flanked by markers that
are in agreement with the common haplotype, and the
mutation would have involved only a single dinucleotide
repeat. However, the order of markers D3S3583,
D3S3578, and D3S3609 is not known. If D3S3609 is
flanked by D3S1618, then D3S1618 would be the only
marker proximal to D3S3609 that conforms to the com-
mon haplotype in patients vwm3 and vwm4. In such a
case, the deviation from the common haplotype at
D3S3609 could very well be the result of a recombi-
nation event.
Interestingly, the patients who are homozygous for the
haplotype have considerable phenotypic variation (van
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Figure 5 Haplotypes shared by Dutch patients who are geographically linked to a rural area in the eastern part of The Netherlands. The
common haplotype was also found in two VWM families from the USA who were of unknown ancestry (patients vwm36-vwm37 and vwm80).
Unblackened, unshaded bars indicate the common genomic regions in at least three families. The gray-shaded block indicates allele 169 of
marker D3S3609, which may have been mutated from allele 171 in the ancestral lineage of patients vwm3 and vwm4.
der Knaap et al. 1998). Patient vwm90 had a severe
phenotype associated with early-onset and rapidly pro-
gressive neurological deterioration. Patients vwm3,
vwm4, and vwm33 had an intermediate phenotype char-
acterized by onset later in childhood and slower neu-
rological deterioration. Patient vwm32 had diagnostic
MRI and MRS findings but remains clinically presymp-
tomatic at the age of 24 years. Apparently, other genetic
or environmental factors influence the course of the
disease.
A recently described gene that codes for oligodendro-
cyte-specific protein (OSP) was localized, by use of FISH,
to the region where the gene for VWM is located (Bron-
stein et al. 1996a). The OSP gene was originally iden-
tified by cDNA cloning of mRNAs that are specific for
the CNS (Bronstein et al. 1996b). On the basis of amino-
acid-sequence comparison, the predicted structure, and
the expression pattern, it was suggested that OSP is a
transmembrane protein that is composed of CNS myelin
and is similar to PMP22 of the peripheral nervous sys-
tem. Mutations in PMP22 are correlated with demye-
linating peripheral neuropathies, including Charcot-Ma-
rie-Tooth disease type 1A, hereditary neuropathy with
liability to pressure palsies, and De´je´rine-Sottas syn-
drome (Roa et al. 1993a; Roa et al. 1993b; Nicholson
et al. 1994). OSP is abundant, like PMP22, and com-
prises 7% of the myelin protein in the CNS (Bronstein
et al. 1997). We considered OSP to be a good candidate
gene for involvement in VWM. We therefore studied the
location of the OSP gene in detail, by means of radiation
hybrid mapping with the Genebridge 4 panel (The In-
ternational RH Mapping Consortium, 1998) (Walter et
al. 1994). The OSP gene maps between loci D3S1564
and D3S3725 (data not shown), a region that is ∼12
cM proximal to the critical region that we identified for
the gene for VWM; this finding excludes OSP as the
gene responsible for VWM.
At least 30 expressed-sequence tags (ESTs) have
been assigned, by radiation hybrid mapping with the
Genebridge 4 panel (The International RH Mapping
Consortium, 1998), to the chromosome-3 interval
that includes the gene for VWM. In this area, the
resolution of this panel is insufficient to align these
ESTs with the polymorphic microsatellite markers of
the critical region for VWM. Known proteins that are
encoded in the region include diacylglycerol kinase
gamma (DAGK3), the transcription-regulator B-cell
lymphoma protein 6 (BCL6), the chloride-channel
protein ClC-2, the protein tyrosine kinase receptor
HEK2 and enoyl-CoA:hydratase 3-hydroxyacyl-CoA
dehydrogenase (the peroxisomal bifunctional protein
EHHADH). Patients with EHHADH deficiency have
been described. The clinical symptoms of this defi-
ciency are dominated by neurological abnormalities.
Demyelination of the cerebral white matter occurs
(Watkins et al. 1989; Wanders et al. 1990). Our group
of patients with VWM did not, however, exhibit the
typical clinical history and metabolic changes that ac-
company EHHADH deficiency (van der Knaap et al.
1997). Nonetheless, we cannot rule out the possibility
that specific mutations in the EHHADH gene cause
the distinct clinical features of VWM. Interestingly,
four different ESTs, which, apparently, are specifically
expressed in the brain, have been localized in the ge-
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nomic interval. These ESTs are NIB1365 (WI-13413);
A004N34, which is weakly similar to DAGK3; sts-
N34433; and WI-13612. We suggest that the corre-
sponding genes are prime candidates for involvement
in VWM.
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